Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma
- PMID: 38483380
- DOI: 10.1001/jamaoncol.2024.0116
Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma
Comment in
-
Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma-Reply.JAMA Oncol. 2024 May 1;10(5):674-675. doi: 10.1001/jamaoncol.2024.0119. JAMA Oncol. 2024. PMID: 38483395 No abstract available.
Comment on
-
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial.JAMA Oncol. 2023 Dec 1;9(12):1651-1659. doi: 10.1001/jamaoncol.2023.4003. JAMA Oncol. 2023. PMID: 37796513 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical